Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

FDA Approves First Generic Strattera for ADHD

By Joanne Van Zuidam | May 31, 2017

The U.S. Food and Drug Administration approved the first generic versions of atomoxetine (Strattera) to treat attention-deficit/hyperactivity disorder (ADHD) in pediatric and adult patients. Atomoxetine is approved for treatment of ADHD in adults and children ages six and older with the disorder.

The patent on Ely Lilly’s Strattera expired on May 26, and multiple drug makers were waiting on FDA approval for their version of the drug.

Apotex Inc., Teva Pharmaceuticals USA Inc., Aurobindo Pharma Limited and Glenmark Pharmaceuticals Limited were granted approval to market the generic in multiple strengths.

The approvals not only brings consumers additional treatments, but meets a goal of the FDA.  “Quickly bringing generics to market so patients have more options to treat their conditions is a top priority for the FDA,” said Kathleen Uhl, M.D., director of the Office of Generic Drugs in the FDA’s Center for Drug Evaluation and Research in a statement.

According to the FDA’s announcement, in clinical trials for atomoxetine in children and adolescents the most common side effects were upset stomach, decreased appetite, nausea or vomiting, dizziness, tiredness, and mood swings. In the clinical trials in adults, the most common side effects reported were constipation, dry mouth, nausea, decreased appetite, dizziness, sexual side effects, and problems passing urine.  

Atomoxetine has a boxed warning for the increased risk of suicidal ideation in children and adolescents.

The medication must be dispensed with a patient Medication Guide that describes the drug’s uses and warnings, said the FDA in a statement. “Patients taking this medication should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the initial few months of a course of drug therapy, or at times of dose changes. Other important warnings include the risk of severe liver damage and potential for serious cardiovascular events.”

Approximately four percent of adults and 11 percent of children in the U.S. are diagnosed with ADHD. Symptoms include inattentiveness, hyperactivity, and impulsivity. Patients with the disorder may be prescribed a stimulant or non-stimulant drug as part of their treatment.

Atomoxetine, a selective norepinephrine reuptake inhibitor, is a non-stimulant drug. The precise mechanism of action is unknown, but is thought to be related to its selective inhibition of presynaptic norepinephrine reuptake in the prefrontal cortex.

 


Filed Under: Drug Discovery

 

Related Articles Read More >

EpicentRx
A next-gen vaccine that could help end COVID-19 whack-a-mole 
Dotmatics
How Dotmatics aims to help reduce the drug discovery failure rate
Diversity
Making diversity in clinical research more than a talking point
psychedelic medicine discussed at SXSW
5 headwinds and 5 tailwinds for psychedelic medicine

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Medtech100 Index
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50